TNF Pharmaceuticals, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Equity (Details Narrative)

Equity (Details Narrative) - USD ($)									3 Months Ended	12 Months Ended
Equity (Details Narrative) - USD ($)	Dec. 21, 2017	Oct. 17, 2017	Oct. 12, 2017	Apr. 11, 2017	Mar. 31, 2017	Mar. 30, 2017	Jan. 13, 2017	Jun. 08, 2016	Jun. 30, 2017	Dec. 31, 2017	Dec. 31, 2016
Administrative expense										$ 4,082,313	$ 3,008,811
Deferred compensation										3,469	$ 24,572
Number of common shares							1,789,500
Issuance of common stock							$ 1,652,994			$ 1,652,994
Number of warrant issued during period										894,750
Warrant exercise price										$ 1.50
Dividend yield											0.00%
Expected volatility											95.02%
Risk free interest rate											1.76%
Expected life											5 years
Sales and marketing expense										$ 1,846,445	$ 1,983,428
Expenses related to the grants										$ 259,694
Preferred shares, issued										1,755	0
Net proceeds from issuance of shares										$ 3,675,000
Common stock, reserved shares										61,445,573
Current Warrant [Member]
Warrant exercise price			$ 1.00
New Warrant [Member]
Warrant exercise price			$ 1.26
Warrant term			5 years
Proceeds from issuance of warrants			$ 671,546
Dividend yield			0.00%
Expected volatility			97.16%
Risk free interest rate			1.95%
Expected life			5 years
Warrants [Member]
Number of warrant issued during period	460,000,001
Warrant exercise price	$ 0.1875
Warrant term	5 years
Fair value of warrants			$ 93,386
Dividend yield			0.00%
Expected volatility			97.16%
Risk free interest rate			1.95%
Expected life			4 years 5 months 19 days
Warrants [Member] \| Maximum [Member]
Warrant exercise price			$ 1.96
Warrants [Member] \| Minimum [Member]
Warrant exercise price			$ 1.00
Warrant Exercise Agreement [Member]
Number of warrant issued during period			724,200
Warrant exercise price			$ 1.96
Proceeds from issuance of warrants			$ 680,748
Other extraordinary expenses			764,932
Proceeds from net of solicitation fee			$ 43,452
Restricted Stock [Member]
Fair value of shares based on share price on date of grant				$ 18,000
Number of warrant issued during period									37,500
Warrant exercise price									$ 1.50
Proceeds from issuance of warrants									$ 56,250
Number of shares issued for services				10,000
Sales and marketing expense										$ 5,455
Shares issued, price per share		$ 0.88
Expenses related to the grants										259,694
Restricted Stock [Member] \| Key Employees and Officers [Member]
Number of common shares		295,107
Restricted Stock [Member] \| December 31, 2018 [Member]
Sales and marketing expense										$ 12,545
Public Offering [Member]
Number of common shares	21,500,000
Number of warrant issued during period					163,300					200,800
Warrant exercise price					$ 1.50					$ 1.50
Warrant term										5 years
Proceeds from issuance of warrants					$ 244,950					$ 301,200
Public Offering [Member] \| Series B Preferred Shares [Member]
Preferred shares, issued	3,675
Net proceeds from issuance of shares	$ 6,065,586
Private Placement [Member]
Number of warrant issued during period										796,620
Warrant exercise price										$ 1.96
Warrant term										5 years
Unregistered shares of common stock						1,448,400
Proceeds from unregistered shares						$ 1,760,317
Administrative Expenses [Member]
Administrative expense										$ 21,103	$ 30,153
Officer [Member]
Number of restricted common stock shares issued during the period								27,500
Stock options vested rights description								These shares vest 1/3 immediately on the date of the grant and the remaining 2/3 vests equally on March 1, 2017 and March 1, 2018.
Fair value of shares based on share price on date of grant								$ 54,725